[Comment] Diminished but not dead: chemotherapy for the treatment of NSCLC

With the safety and efficacy of immune checkpoint inhibitors in previously treated patients with advanced non-small-cell lung cancer (NSCLC) established,1–3 recent studies have focused on their use in the first-line setting. Data from several single-arm phase 1 cohorts have suggested increased efficacy of PD-1 inhibitors in the first-line setting.4 The recently published Keynote-024 trial randomly assigned 305 patients with treatment-naive, advanced NSCLC with PD-L1 expression in at least 50% of tumour cells to receive either the PD-1 inhibitor pembrolizumab or platinum-based chemotherapy according to investigator's choice.

http://ift.tt/2f6OmRD